Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | CASP3 | P42574 | 1/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.36 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.36 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1706615 | 0.85 | FPR2 (0.81) | FPR2MEN1KMT2APKMCASP3 | |
| SCHEMBL1705770 | 0.81 | FPR2 (0.60) | FPR2MEN1KMT2APKMCASP3 | |
| SCHEMBL1706175 | 0.78 | FPR2 (0.45) | FPR2MEN1KMT2ASCN9AHPGD | |
| SCHEMBL1166575 | 0.76 | MEN1 (0.43) | MEN1KMT2APKMCASP3SENP8 | |
| SCHEMBL1705829 | 0.74 | FPR2 (0.51) | FPR2MEN1KMT2APKMCASP3 | |
| SCHEMBL1167266 | 0.72 | MEN1 (0.43) | MEN1KMT2APKMCASP3SENP8 | |
| SCHEMBL1706228 | 0.72 | FPR2 (0.49) | FPR2MEN1KMT2APKMCASP3 | |
| SCHEMBL1705811 | 0.71 | FPR2 (0.46) | FPR2MEN1KMT2APKMCASP3 | |
| SCHEMBL5015677 | 0.69 | FPR2 (0.40) | FPR2MEN1KMT2APKMCASP3 | |
| SCHEMBL5015698 | 0.69 | FPR2 (0.40) | FPR2MEN1KMT2APKMCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8674111-B2 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-18 | — | — | US | claimed |
| EP-2440536-B1 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-06 | — | — | EP | claimed |
| US-20120115916-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | claimed |
| EP-2440536-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-04-18 | — | — | EP | claimed |
| WO-2010143158-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-12-16 | — | — | WO | claimed |
| US-8674111-B2 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-03-18 | — | — | US | disclosed |
| EP-2440536-B1 | Oxazole and thiazole derivatives as ALX receptor agonists | ACTELION PHARMACEUTICALS LTD (CH) | 2013-11-06 | — | — | EP | disclosed |
| US-20120115916-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| EP-2440536-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143158-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115916-A1 | OXAZOLE AND THIAZOLE DERIVATIVES AS ALX RECEPTOR AGONISTS | P2RX1, GLP1R, P2RX7 | FPR2 156/4885MEN1 3615/4885KMT2A 3711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.